FAST NEWS: Simcere Pharmaceutical Grants Overseas Rights for Drug Candidate
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) announced Thursday that it granted Almirall S.A. exclusive rights to develop and commercialize its autoimmune drug candidate SIM0278 outside of Greater China. Looking up: Simcere…
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
- As Covid drug cash dwindles, Vigonvita targets new remedies
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
